, 2003, 13(5), 199–200
These achievements, which constitute an overall six-step
enantioselective synthesis of (AcP)ala 4 from inexpensive
achiral and racemic starting materials, not only facilitate the
forthcoming total synthesis of belactosin A 2 but also approach
to synthetic analogues of naturally occurring small peptides to
modify their biological activity. For example, the (2S,1'S,2'R)-
3-(trans-2-aminocyclopropyl)alanine [(2S,1'S,2'R)-4] has re-
cently been incorporated instead of the corresponding (NcP)ala
[(2S,1'R,2'R)-3] in the side chain of hormaomycin 1 in order
to be able to test the potential biological activity of modified
peptidolactones of the hormaomycin type.
rac-3·HCl
H2N
NH3Cl
NH3Cl
ClH3N
NO2
[H]
CO2H
Conditions
CO2H
rac-4·HCl
rac-3·HCl
H2N
CO2H
rac-7·HCl
This work was supported by Deutsche Forschungsgemein-
schaft (SFB 416, Project A3) and Bayer AG (Leverkusen). We
are indebted to BASF AG, Bayer AG, Chemetall GmbH, and
Degussa AG for generous gifts of chemicals. We are grateful
to Professor Yu. N. Belokon, A. N. Nesmeyanov Institute of
Organoelement Compounds (Moscow), for fruitful discussions,
and to Dr. B. Knieriem for his careful reading of the final
manuscript.
Scheme 2
conditions in anhydrous methanol afforded the desired cyclo-
propyl-containing rac-4 as the sole product.
Under these conditions, (2S,1'R,2'S)-, (2S,1'S,2'R)-,
(2R,1'S,2'R)-, and (2R,1'R,2'S)-3-(2-aminocyclopropyl)alanines
4 were obtained from corresponding (2S,1'S,2'S)-, (2S,1'R,2'R)-,
(2R,1'R,2'R)-, and (2R,1'S,2'S)-3-(2-nitrocyclopropyl)alanines 3
in 95, 93, 91 and 92% yields, respectively (Scheme 3).†
References
1 (a) J. Salaün and M. S. Baird, Curr. Med. Chem., 1995, 2, 511; (b)
103, 1625.
H2N
NO2
H2N
NH2
CO2H
(2S,1'R,2'S)-4 (95%, ee 96%)
CO2H
(2S,1'S,2'S)-3
2 (a) N. Andres, H. Wolf, H. Zähner, E. Rössner, A. Zeeck, W. A. König
and V. Sinnwell, Helv. Chim. Acta, 1989, 72, 426; (b) E. Rössner,
A. Zeeck and W. A. König, Angew. Chem., 1990, 102, 84 (Angew. Chem.,
Int. Ed. Engl., 1990, 29, 64).
3 (a) A. Asai, A. Hasegawa, K. Ochiai, Y. Yamashita and T. Mizukami, J.
Antibiotics, 2000, 53, 81; (b) A. Asai, T. Mizukami, Y. Yamashita,
S. Akinaga, S. Ikeda and Y. Kanda, Eur. Patent, 1166781, 2002 (Chem.
Abstr., 2002, 133, 120677h).
H2N
NO2
H2N
NH2
CO2H
CO2H
(2S,1'S,2'R)-4 (93%, ee 99%)
(2S,1'R,2'R)-3
H2N
H2, Pd/C (10 mol%)
NO2
NO2
H2N
NH2
MeOH, 20 °C,
5 M. Brandl, S. I. Kozhushkov, K. Loscha, O. V. Kokoreva, D. S. Yufit,
J. A. K. Howard and A. de Meijere, Synlett, 2000, 1741.
24 h
CO2H
CO2H
(2R,1'S,2'R)-4 (91%, ee 96%)
(2R,1'R,2'R)-3
the configurations of the four diastereomers of 3-(trans-2-nitrocyclo-
propyl)alanines 3 were drawn correctly, but the R,S-nomenclature was
applied wrongly.
190; (c) J. Zindel and A. de Meijere, J. Org. Chem., 1995, 60, 2968; (d)
J. Zindel, Dissertation, Universität Göttingen, 1993.
H2N
H2N
NH2
CO2H
CO2H
(2R,1'R,2'S)-4 (92%, ee 99%)
(2R,1'S,2'S)-3
Scheme 3
†
General procedure for hydrogenative transformation of the [(NcP)ala]
diastereomers into the corresponding (aminocyclopropyl)alanines
[(AcP)ala]. To a solution of enantiomerically pure amino acid 3
(348 mg, 2.0 mmol) in anhydrous MeOH (160 ml) was added Pd/C
(Merck, 10% Pd, 0.2 mmol, 0.21 g). The mixture was vigorously stirred
under H2 (1 bar) at 20 °C for 24 h. The catalyst was filtered off, the
filtrate was concentrated under reduced pressure to give desired
(2S,1'R,2'S)-, (2S,1'S,2'R)-, (2R,1'S,2'R)-, and (2R,1'R,2'S)-3-(trans-2-
aminocyclopropyl)alanines 4 in 95, 93, 91 and 92% yields, respectively,
after recrystallization from PriOH–H2O.
(2S,1'R,2'S)-4: colourless solid, mp 148 °C (decomp.), [a]D20 +29.3°
(c 0.6, H2O). H NMR (250 MHz, D2O) d: 0.60 (ddd, 1H J 5.9, 6.3,
1
7.2 Hz), 0.77 (m, 1H), 0.97 (m, 1H), 1.68 (m, 1H), 1.81 (m, 1H), 2.28
(m, 1H), 3.66 (t, 1H, J 6.2, 6.2 Hz). 13C NMR (62.9 MHz, D2O) d: 13.97
(CH2), 17.07 (CH), 31.67 (CH), 36.51 (CH2), 57.24 (CH), 179.66 (C).
IR (n/cm–1): 3629, 3056, 2953, 1733, 1630, 1587.
(2S,1'S,2'R)-4: colourless solid, mp 150 °C, [a]D20 –37.8° (c 0.4, H2O).
1H NMR (250 MHz, D2O) d: 0.60 (ddd, 1H, J 5.8, 6.5, 7.3 Hz), 0.76 (m,
1H), 0.92 (m, 1H), 1.71 (m, 1H), 1.80 (m, 1H), 2.23 (m, 1H), 3.63 (ddd,
1H, J 5.7, 5.7, 5.8 Hz). 13C NMR (62.9 MHz, D2O) d: 14.19 (CH2),
17.33 (CH), 31.88 (CH), 36.70 (CH2), 57.82 (CH), 179.69 (C). IR
(n/cm–1): 3359, 3072, 2927, 1617, 1406, 1322.
(2R,1'S,2'R)-4: colourless solid, mp 153 °C (decomp.), [a]D20 –29.1°
(c 0.4, H2O). 1H, 13C NMR and IR spectra are virtually identical to those
of (2S,1'R,2'S)-4.
(2R,1'R,2'S)-4: colourless solid, mp 148 °C (decomp.), [a]D20 +37.7°
(c 0.6, H2O). 1H, 13C NMR and IR spectra are virtually identical to those
of (2S,1'S,2'R)-4.
Received: 30th June 2003; Com. 03/2143
– 200 –